Ratutrelvir

Ratutrelvir
Clinical data
Other names	83-0060, TRX01
Identifiers
	IUPAC name (1R,2S,5S)-N-[(1S)-1-cyano-2-(2-oxo-1,3-dihydroindol-3-yl)ethyl]-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide;
CAS Number	2929236-94-0;
PubChem CID	169861725;
IUPHAR/BPS	13737;
UNII	VR2S5588W2;
Chemical and physical data
Formula	C27H32F3N5O4
Molar mass	547.579 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)C(F)(F)F)C(=O)N[C@@H](CC3C4=CC=CC=C4NC3=O)C#N)C;
	InChI InChI=InChI=1S/C27H32F3N5O4/c1-25(2,3)20(34-24(39)27(28,29)30)23(38)35-12-16-18(26(16,4)5)19(35)22(37)32-13(11-31)10-15-14-8-6-7-9-17(14)33-21(15)36/h6-9,13,15-16,18-20H,10,12H2,1-5H3,(H,32,37)(H,33,36)(H,34,39)/t13-,15?,16-,18-,19-,20+/m0/s1; Key:VVIHXCHAXVESGZ-MXEWLHNESA-N;

Ratutrelvir is an investigational new drug that is being evaluated by Traws Pharma^[1] for the treatment of COVID-19 infections.^[2]^[3] It is a 3C-like protease inhibitor.^[3]^[4]

Clinical trials

Ratutrelvir is currently in a phase 2 clinical trial to test the effectiveness and safety of the drug in patients with COVID-19^[5] and a preliminary analysis of the results has been released.^[6]

References

↑ WO 2023245162, Rogovoy B, Kysil V, Berishvili V, Pauza CD, Zapata JC, Moreno SM, Li H, Orry A, Lam PC, Abagyan R, Savchuk N, "Compounds for treatment a coronavirus infection", published 2023-12-21, assigned to Trawsfynydd Therapeutics Inc.
↑ "International Nonproprietary Names for Pharmaceutical Substances (INN) Recommended INN: List 94" (PDF). WHO Drug Information. 39 (3). World Health Organization: 809–1060 (976). 2025.
1 2 "Travatrelvir - Traws Pharma". AdisInsight. Springer Nature Switzerland AG. Retrieved 5 July 2026.
↑ "Ratutrelvir | Ligand page". IUPHAR/BPS Guide to PHARMACOLOGY.
↑ "Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19". ClinicalTrials.gov. U.S. National Library of Medicine. 17 January 2026. Clinical trial record for NCT07157007. Retrieved 5 July 2026.
↑ Contagion Editorial Team (8 July 2026). "Traws Pharma Reports Differentiated COVID-19 and Influenza Antiviral Progress". Contagion Live.

[1] WO 2023245162, Rogovoy B, Kysil V, Berishvili V, Pauza CD, Zapata JC, Moreno SM, Li H, Orry A, Lam PC, Abagyan R, Savchuk N, "Compounds for treatment a coronavirus infection", published 2023-12-21, assigned to Trawsfynydd Therapeutics Inc.

[2] "International Nonproprietary Names for Pharmaceutical Substances (INN) Recommended INN: List 94" (PDF). WHO Drug Information. 39 (3). World Health Organization: 809–1060 (976). 2025.

[AdisInsight_ratutrelvir-3] 1 2 "Travatrelvir - Traws Pharma". AdisInsight. Springer Nature Switzerland AG. Retrieved 5 July 2026.

[4] "Ratutrelvir | Ligand page". IUPHAR/BPS Guide to PHARMACOLOGY.

[NCT07157007-5] "Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19". ClinicalTrials.gov. U.S. National Library of Medicine. 17 January 2026. Clinical trial record for NCT07157007. Retrieved 5 July 2026.

[6] Contagion Editorial Team (8 July 2026). "Traws Pharma Reports Differentiated COVID-19 and Influenza Antiviral Progress". Contagion Live.

[1]

[2]

[3]

[4]

[5]

[6]